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Basal cell carcinoma (BCC), the most
common and most visible of all human
tumors, frequently arises on sun-exposed
skin and can produce extensive local
damage if left untreated. Targeted thera-
peutics are now available that interfere
with uncontrolled Hedgehog (Hh) signal-
ing, the molecular hallmark of BCC,
ushering in a new era in cutaneous
oncology. This review describes some
of the pivotal work that contributed to
our current understanding of BCC and
Hh signaling, and ultimately led to the
development of drugs targeting the Hh
pathway in BCC patients.
NBCCS AND THE GENETIC BASIS OF BCC
The first published report of sporadic
skin tumors resembling BCCs dates
back to 1827 (Jacob, 1827), and in
1960, Gorlin and Goltz described an
autosomal dominant syndrome charac-
terized by an increased predisposi-
tion to BCC development (Gorlin and
Goltz, 1960). Individuals with Nevoid
Basal Cell Carcinoma Syndrome
(NBCCS) develop BCCs at an earlier
age than the general population and
with greater frequency, with some
patients developing hundreds of
tumors over their lifetime. Other neo-
plasms also arise with greater
frequency in these individuals, parti-
cularly the pediatric brain tumor
medulloblastoma, and these indivi-
duals frequently develop locally
destructive jaw cysts as well as other
abnormalities involving bone and
other tissues (Kimonis et al., 1997).
The occurrence of cancer together
with clinical findings thought to be
the consequence of developmental
aberrations suggested that defects in an
embryonic signaling pathway were res-
ponsible for NBCCS. This was confir-
med in 1996, when two groups reported
that NBCCS patients harbor loss-of-func-
tion mutations in PTCH1 (Hahn et al.,
1996; Johnson et al., 1996) that encodes
a receptor for the Hh family of embryo-
nic signaling proteins (Stone et al., 1996).
Importantly, sporadic BCCs were also
found to have mutations in PTCH1,
pointing to a role for this gene in BCCs
arising in the general population. NBCCS
patients carry a mutant PTCH1 allele
in all cells and the remaining normal
allele is lost in BCCs, arguing that
PTCH1 functions as a classic tumor
suppressor.
THE HEDGEHOG PATHWAY IN
DEVELOPMENT
The identification of loss-of-function
PTCH1 mutations in the majority of
BCCs pointed to a causal role for this
genetic defect in tumorigenesis; how-
ever, to appreciate the functional con-
sequence of PTCH1 deficiency on Hh
signaling, it was important to under-
stand how this pathway is normally
regulated. Hh was first described in
1980 by Christiane Nu¨sslein-Volhard
and Eric Wieschaus (Nusslein-Volhard
and Wieschaus, 1980), who generated
and characterized multiple classes
of Drosophila mutants with visible
alterations in patterning of the early
embryo. In one group of embryos, the
highly patterned ventral organization of
hairs, alternating with hairless stripes,
was replaced by a continuous lawn
of short, stubby hairs reminiscent of a
hedgehog’s spines, and hence the
moniker for this mutant. In 1995,
Nu¨sslein-Volhard and Wieschaus
shared the Nobel Prize with Edward
Lewis for their discoveries that provided
fundamental insight into the genetic
regulation of early embryogenesis—
discoveries with great relevance to
human biology and disease, as exempli-
fied by the central role of Hh pathway
alterations in BCC pathogenesis.
Hh is one of a handful of key
signaling pathways that orchestrates
embryogenesis by exerting both spatial
and temporal control over prolifera-
tion, survival, and cell-fate decisions.
In the absence of Hh proteins, Ptch1
blocks the function of a key signaling
effector in the Hh pathway called
Smoothened (Smo) (Figure 1, upper
panel). Signaling is initiated when
secreted Hh ligands bind Ptch1 on
target cells and inhibit its function,
leading to derepression of Smo, sub-
sequent activation of downstream Gli
transcription factors, and upregulation
of Hh target genes. Physiologic signal-
ing is generally paracrine, with differ-
ent cell populations producing and
responding to Hh, and is strictly
dependent on the presence of Hh
ligand, so that repression of Smo by
Ptch1 is restored in the absence of Hh
protein.
Gene deletion studies targeting Sonic
hedgehog (Shh), the predominant Hh
ligand in mammals, have established
a requirement for the Hh pathway in
the embryonic development of many
tissues and organs. Perhaps most strik-
ingly, Shh-null mice possess severe
defects in craniofacial development
owing to a requirement for Hh signal-
ing for proper division of the forebrain
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into cerebral hemispheres and the
primordial eye field into two eyes. This
results in a single, centrally located eye
in Shh-deficient embryos (cyclopia)
(Chiang et al., 1996), consistent with
similar findings in human fetuses carry-
ing mutations in SHH (Belloni et al.,
1996; Roessler et al., 1996). Cyclopia
is thus a highly characteristic pheno-
type caused by disruption of Hh
signaling during embryogenesis, an
observation that figured prominently
in the discovery of Hh pathway antago-
nists, as discussed below. Although Hh
pathway activity is detected in several
adult organs, studies in mice have
identified essential functions in just a
few. Most notable among these is the
hair follicle that is strictly dependent on
Hh signaling for growth and hair shaft
elongation (Wang et al., 2000).
HEDGEHOG PATHWAY DEREGULATION IN
CANCER
In the great majority of BCCs, the Hh
pathway is deregulated because of
disruption of the signaling repressor
PTCH1, but in a minority of tumors, a
mutant form of SMO is present (Xie
et al., 1998) that is insensitive to
inhibition by PTCH1 (Figure 1, lower
panel). The result in both cases is
constitutive, ligand-independent Hh
signaling in epithelial cells attributable
to unrestrained SMO activity. Essen-
tially all BCCs have an activated Hh
pathway as evidenced by high-level
expression of Hh target genes, suggest-
ing that this signaling alteration plays
a central role in tumor pathogenesis.
This concept has been supported by
mouse modeling studies that used
either transgenic approaches, in which
positive regulators of the Hh path-
way (Shh, oncogenic SMO, GLI1,
Gli2) were overexpressed in skin
(Oro et al., 1997; Xie et al., 1998;
Grachtchouk et al., 2000; Nilsson
et al., 2000; Grachtchouk et al.,
2003), or gene deletion studies, to
generate mice with a disrupted Ptch1
allele mimicking the genetic defect in
NBCCS patients (Aszterbaum et al.,
1999). These studies have established
that uncontrolled Hh signaling is suffi-
cient for promoting BCCs and BCC-like
tumors in mice, and that sustained Hh
pathway activity is required for BCC
maintenance (Hutchin et al., 2005).
What about other cancers? Medullo-
blastomas associated with Hh pathway
deregulation are similar to BCCs in that
they are driven by ligand-independent
Hh signaling, in keeping with their
increased incidence in NBCCS patients
and Ptch1-deficient mice (Goodrich
et al., 1997). A small proportion of
medulloblastomas harbor oncogenic
mutations in SMO, similar to BCCs.
Hh signaling has also been implicated
in the pathogenesis of various internal
malignancies (e.g., pancreatic cancer,
gastric cancer, prostate cancer, small-
cell lung cancer). In contrast to
BCC and medulloblastoma, in visceral
cancers the stromal cells frequently
exhibit elevated Hh signaling because
of increased production of Hh ligand(s)
by tumor cells, mirroring the paracrine
mode of Hh pathway activation that
is common during development
(reviewed in Barakat et al., 2010). The
discovery of heightened Hh path-
way activity in several life-threatening
internal malignancies has generated
intense interest in targeting this path-
way for the treatment of neoplasms
other than BCC and medulloblastoma.
DIFFERENT SUBTYPES OF BCC
Like many tumors, BCCs can be classi-
fied into several subtypes based on
morphology and differentiation. The
superficial and nodular subtypes of
BCC are indolent, and are thought to
arise from progenitor cells located in
the epidermis and within the hair
follicle, respectively. In contrast, the
cellular origins of the more aggressive
variants, including infiltrative, baso-
squamous, and morpheaform or sclero-
sing BCCs, are unclear. These aggressive
subtypes frequently cause local tissue
damage, are often not circumscribed by
a basement membrane, and may be
associated with fibroplasia, suggesting
that stromal communication via para-
crine signals may also be especially
important in these tumors.
How the seemingly diverse varia-
tions of BCC are manifest currently
remains unclear. The hair follicle itself
comprises at least eight related epi-
thelial cell lineages, and both tumor
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Figure 1. Simplified diagram illustrating physiologic versus oncogenic Hedgehog (Hh) signaling. Red
shading indicates negative regulators whereas green indicates positive regulators of Hh signaling. BCC,
basal cell carcinoma.
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morphology and behavior may be
influenced by the particular cellular
lineage that sustains the initial onco-
genic hit to the Hh pathway. BCC-like
lesions arising from different experi-
mental mouse models of BCC often
exhibit diverse morphologies with
varying degrees of resemblance to
human BCCs, as will be described in
detail below. These findings suggest
that the nature of the genetic mutation
may also affect BCC subtype. Finally,
and perhaps most importantly, the
amplitude of Hh pathway activation
may underlie many of these variations.
Indeed, studies in transgenic mice
have suggested that high activation
of Hh signaling can elicit BCC-like
lesions that more closely resemble
classical forms of nodular human
BCCs, whereas low pathway activity
induces the formation of tumors resem-
bling benign basaloid hamartomas
(Grachtchouk et al., 2003, 2011).
In turn, the degree of Hh signaling
likely impinges upon, and conversely
may be affected by, synergistic
activation of other pathways such as
Wnt, epidermal growth factor receptor,
phosphatidylinositol 3 kinase/mamma-
lian target of rapamycin, and p53.
Thus, cell of origin, the nature of the
genetic mutation, the degree of Hh
pathway activation, and synergy with
other collaborating pathways are likely
all key determinants of BCC morpho-
logy and behavior.
CELL OF ORIGIN
Where do BCCs come from? Over the
past few years, with the creation of
numerous mouse models of cancer
as well as the tools to manipulate genes
in specific cell populations, much
research has been devoted toward
filling in our knowledge about the
origin story for different cancers—
unmasking the identity of the initial
cells that, upon sustaining a genetic
mutation, can give rise to tumors
(Visvader, 2011). For decades, BCCs
have been presumed to arise either
from the basal layer of the epidermis
or from the hair follicle outer root
sheath. Evidence for this was indirect,
and based primarily on histology and
similarities in cytokeratin expression
between tumor lesions and their
normal cellular counterparts. More
recently, in the aforementioned mouse
models of BCCs, attempts to elucidate
the cellular origin for these lesions
were based on somewhat circum-
stantial observations made at early
stages of tumor development, and
various reports have claimed that
BCCs arise from both epidermis and
hair follicles.
Part of the difficulty in identifying the
cellular origin for BCC is that skin is a
complex organ. This has become espe-
cially apparent over the past few years,
as genetic lineage tracing has led to the
identification of multiple independent
stem cell populations in the hair follicle
and epidermis that operate inde-
pendently during homeostasis, but
can exhibit plasticity during patho-
logical situations such as wounding.
This complexity may, at least in part,
underlie the seemingly contradictory
results reported recently by multiple
groups regarding the cellular origin for
BCC (reviewed in Kasper et al., 2012).
For instance, BCC-like tumors induced
by an oncogenic form of Smo have
been reported to arise primarily from
the interfollicular epidermis, but not
from hair follicle bulge stem cells,
except upon wounding (Youssef et al.,
2010; Kasper et al., 2011; Wong and
Reiter, 2011). In direct contrast, lineage
tracing studies have suggested that
bulge cells give rise to the majority of
BCCs in irradiated Ptch1 heterozygous
mice (Wang et al., 2011).
Reconciling these conflicting results
may have important implications for
understanding why BCCs can exhibit
such diverse morphologies. Indeed,
additional studies have shown that BCCs
induced by a truncated form of GLI2
exhibit high-level pathway activation
and can arise from both the epidermis
and the hair follicle lower bulge or
secondary hair germ (Grachtchouk
et al., 2011). Notably, tumors origina-
ting from the epidermis resembled super-
ficial BCCs, whereas nodular tumors
were associated with the follicle, sugges-
ting that cell of origin may indeed
influence tumor subtype.
Thus, although these seemingly con-
flicting results have provoked some
confusion in the field, from a wider
standpoint these studies may also
suggest that perhaps the cellular origin
for BCC may not be fixed and immu-
table, but rather may depend on the
nature of the genetic mutation and the
degree of Hh pathway activation as
well as on stromal context.
ONE-EYED LAMBS AND HEDGEHOG
PATHWAY INHIBITION
The identification of the first pharma-
cological inhibitor of Hh signaling was
based on a series of pivotal observa-
tions and discoveries dating back to the
1950s (Figure 2), when up to 25% of
lambs on certain Idaho ranches were
born with severe craniofacial deformi-
ties, including a single eye (cyclopia)
(reviewed in Keeler, 1978). The disco-
very that all pregnant ewes that pro-
duced cyclopic lambs grazed in areas
with similar flora raised the possibility
of an environmental teratogen. This
was confirmed in 1963 when it was
shown that feeding pregnant ewes the
corn lily, Veratrum californicum, also
produced cyclopic lambs (Binns et al.,
1963), and several years later the
primary teratogen responsible for this
phenotype was identified and named
cyclopamine (Keeler and Binns, 1966).
Nearly 30 years later, genetic studies
have established that cyclopia in both
humans and mice is caused by
impaired Hh signaling (Belloni et al.,
1996; Chiang et al., 1996; Roessler
et al., 1996), raising the exciting possi-
bility that cyclopamine is teratogenic
because it blocks the Hh pathway.
Subsequent studies confirmed that
cyclopamine is a Hh pathway inhibi-
tor (Cooper et al., 1998), physically
interacts with the Hh signaling effector
Smo (Chen et al., 2002), and can
block oncogenic Hh signaling (Taipale
et al., 2000). Small-molecule screens
identified other Hh pathway inhibitors
with improved pharmacological pro-
perties that also block Smo, and several
of these have yielded promising results
in preclinical studies that have led to
clinical trials in patients with locally
advanced or metastatic BCC and
medulloblastoma. Favorable clinical
responses to one of these inhibitors,
vismodegib (GDC-0449), led to its
approval by the Food and Drug
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Administration in early 2012 for the
treatment of locally advanced or
metastatic BCC. Multiple other SMO
antagonists are currently in trials, and
additional inhibitors are being examined
that target different components of the
Hh pathway or interacting pathways
(reviewed in Amakye et al., 2013).
CLINICAL USE OF HEDGEHOG PATHWAY
INHIBITORS
Results of the initial clinical reports
showing efficacy of Hh pathway inhi-
bition using vismodegib in BCC and
medulloblastoma were published in
2009. The BCC study demonstrated
efficacy in both locally advanced and
metastatic BCCs (Von Hoff et al.,
2009), and this was subsequently con-
firmed in a larger cohort (Sekulic et al.,
2012). The response rate in the latter
study was 43% for locally advanced
BCC (21% of patients were clear of
disease), and 30% for patients with
metastatic BCC that is highly treatment
resistant and carries a poor prognosis.
The medulloblastoma case report
documented a rapid but short-lived
therapeutic response in an adult
patient with widespread metastatic
disease: nearly all tumors regressed
within 2 months of treatment, but 1
month later, tumors had regrown
despite continued drug treatment
(Rudin et al., 2009). As previously
shown for other cancer therapeutics
targeting pivotal oncogenic drivers,
resistant tumors expressed a mutant
form of SMO that no longer bound
the drug (Yauch et al., 2009). Although
resistance also develops in a subset of
BCCs during treatment with vismo-
degib, this is relatively uncommon
and observed primarily in advanced
tumors from patients who may have
been previously exposed to mutagenic
treatments.
In a more recent BCC study, essen-
tially all preexisting tumors in NBCCS
patients regressed during vismodegib
treatment. In addition, the clinical
appearance of new BCCs was blocked
(Tang et al., 2012), arguing that Hh
pathway inhibition may provide an
effective prevention strategy for
certain high-risk patients. This report
also showed that despite striking
regression and apparent clearing of
preexisting tumors, discontinuation of
treatment led to tumor regrowth. These
results were anticipated several years
earlier based on studies using a condi-
tional mouse model examining BCC
regression and recurrence following
reversible genetic modulation of Hh
signaling (Hutchin et al., 2005).
Treatment with vismodegib and
other systemic Hh pathway inhibitors
is associated with several side effects,
including muscle cramps, alterations in
taste perception, weight loss (presum-
ably related to taste alterations), and
alopecia (Tang et al., 2012), and these
are severe enough to drive some
patients to discontinue treatment.
Development of alopecia is not
surprising given the established role of
Hh signaling in hair growth, and the
expression of Hh pathway components
in taste organs suggests that taste
disturbances may also reflect on-target
side effects. Understanding the mecha-
nisms underlying Hh pathway inhibitor-
associated toxicities may uncover pre-
viously unappreciated functions for Hh
signaling in adult organs and may lead to
approaches to mitigate side effects.
The location of BCCs makes them
ideally suited for medical treatment
using topical or intralesional therapy
that should lessen or eliminate side
effects associated with systemic treat-
ment. Two studies using topical Hh
pathway antagonists have been repor-
ted. In one, the treatment was ineffec-
tive probably owing to a lack of Hh
pathway blockade, despite the fact that
the drug (CUR61414) was effective in
preclinical trials in mice (Tang et al.,
2011). The second study documented
effective inhibition of Hh signaling
and either a reduction in tumor size,
or clinical clearing, within 4 weeks
of treatment with a topical formulation
of the Hh pathway inhibitor LDE225
(Skvara et al., 2011).
The availability of vismodegib and
other systemic Hh pathway antagonists
provides an important new addition to
the treatment armamentarium for
patients with advanced and metastatic
BCCs and, in some cases, is likely
extending the lives of these individuals.
However, it remains too early to know
whether systemic or topical/intra-
lesional treatment will be useful, either
as monotherapy or as a neoadjuvant, in
less advanced tumors that represent a
vast majority of BCCs. Also currently
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Figure 2. Milestones leading to the identification and targeting of deregulated Hedgehog (Hh) signaling in basal cell carcinoma (BCC). FDA, Food and Drug
Administration; NBCCS, nevoid basal cell carcinoma syndrome; Tx, treatment.
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unclear is whether Hh pathway inhibi-
tors may serve as a preventative in
high-risk patients. Regardless, it seems
likely that Hh pathway inhibitors of
one type or another will play an increa-
singly important role in the medical
management of at least some patients,
and perhaps many, with BCC.
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